REVELATION BIOSCIENCES, INC. Increase (Decrease) in Derivative Liabilities
REVELATION BIOSCIENCES, INC. (REVB) reported Increase (Decrease) in Derivative Liabilities of $1.66 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-06-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2021-06-22
- REVELATION BIOSCIENCES, INC. increase (decrease) in derivative liabilities for the quarter ending 2021-03-31 was $1.66M.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month |
|---|---|
| 2021-03-31 | $1.66M 10-Q · filed 2021-06-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |